Astute Medical Logo
Innovative biomarkers.  Smarter healthcare.


Critical Care Symposium to Highlight New Risk Assessment Biomarkers

SAN DIEGO – October 11, 2012 —Astute Medical, Inc. today announced it will discuss risk assessment of acute kidney injury (AKI) in critically ill patients at a symposium to be held in conjunction with the upcoming European Society of Intensive Care Medicine (ESICM) congress in Lisbon, Portugal. The Company-hosted symposium, “New AKI Biomarkers: A Revolution in Risk Assessment,” will be held on Monday, October 15, 2012, from 12:30 to 14:00 local time. Interested participants can visit to register online and can follow via Twitter @ACuteKidneyMan.

The educational session, which is open to ESICM attendees, will feature clinical presentations from experts performing groundbreaking work in the areas of critical care medicine and AKI. Speakers will offer insights for physicians with patients affected by AKI and address the challenges and potential advances in the management of these patients.

“AKI is known to be devastating from a health and cost perspective. Advances in the area of risk assessment could be key to changing outcomes,” said presenter Dr. John Kellum, professor of critical care medicine at the University of Pittsburgh School of Medicine. “By identifying possible mechanisms of injury, novel biomarkers may also increase our understanding of AKI, how to detect it early and how to design and initiate measures to improve patient care.”

In addition to Dr. Kellum, the educational event features renowned faculty including, Dr. Claudio Ronco, Dr. Michael Joannidis, Dr. Lakhmir Chawla, Dr. Eric Hoste and Dr. Patrick Honoré.

Astute Medical is an exhibitor at ESICM, one of the most prestigious critical care conferences. Throughout the ESICM meeting, Astute Medical representatives will be available at Booth 19 in Exhibition Area A to discuss the Company's focus on the risk assessment of AKI in critically ill patients and to preview the Nephrocheck™ Test, a risk assessment tool that Astute Medical plans to launch in 2012. The Nephrocheck™ Test is not available for sale in the United States.

About Astute Medical, Inc.
Astute Medical is dedicated to improving the diagnosis of high-risk medical conditions and diseases through the identification and validation of protein biomarkers that can serve as the basis for novel diagnostic tests. The Company’s focus is community- and hospital-acquired acute conditions that require rapid diagnosis and risk assessment. Astute Medical’s current areas of interest include abdominal pain, acute coronary syndromes, cerebrovascular injury, kidney injury and sepsis. For additional information, please


ASTUTE MEDICAL,TM the Astute Medical logo, Nephrocheck,™ the Nephrocheck™ logo andAstute140™are trademarks of Astute Medical, Inc.

Media Contact:
Law Padilla Communications
Nadine Padilla
(619) 507-9306

©2019 Astute Medical, Inc. Astute Medical®, the AM logo, Astute140®NephroCheck®, the NephroCheck® logo, and AKIRisk® are registered trademarks of Astute Medical, Inc. in the United States. For information regarding trademarks and other intellectual property applicable to this product, including international trademarks, please see PN 0276 Rev A 2014/06/17